Accurate patient stratification remains one of the most pressing challenges in the development of novel targeted therapeutics. MAA (Molecular Affinity Analysis) enables detection of therapeutically relevant regions for targeted therapies like ADCs, CAR-T, RLTs, etc., to assess whether a given therapeutic can bind to its intended targets in tumor tissues. Unlike conventional IHC or genetic assays, MAA mimics the therapeutic itself, offering a way to directly assess drug-target engagement in fixed patient samples. This provides valuable insight into binding-site accessibility, supporting target validation, patient stratification, and translational research.
Not all drugs that target the same protein will bind equally — or at all — in patient tissues. Despite being designed for the same molecular target, targeted therapeutics like ADCs, CAR-T and RLTs can show dramatically different binding profiles depending on their specific epitope, the tumor microenvironment, and structural accessibility. These differences are often insufficiantly portrait in conventional diagnostics like IHC, FISH, or sequencing. By detecting therapeutically relevant regions, MAA provides insight into drug-target engagement in tissue that complements conventional assays, supporting translational research and patient stratification.
MAA enables multiplexed visualization of multiple targets of interest within the same tumor section. This allows researchers to map spatial binding patterns, identify distinct tumor subpopulations, and uncover co-expression or exclusivity of therapeutic targets. By showing how different targeted therapeutics bind across the tumor landscape, MAA multiplexing supports the generation of hypotheses around combination strategies, optimal treatment sequencing, and potential mechanisms of resistance.
MAA (Molecular Affinity Analysis) provides a precise and versatile platform for detecting therapeutic binding sites on tumor tissues. It offers high specificity and sensitivity, enabling in situ quantification of binding site accessibility and density.
MAA integrates seamlessly into various workflows, from preclinical drug development to exploratory clinical research, supporting applications such as drug-target interaction mapping, patient stratification, and therapy exploration for challenging cases. It serves researchers, clinical trial investigators, and drug developers alike, across all stages of the scientific and clinical development pathway. The platform supports precision in oncology research by delivering molecular insights relevant to the drug development pipeline.
For more information or to get started, please reach out to us at info@bav.bio or use the contact form below. Our team will respond promptly to assist with your inquiry and provide the information you need. We look forward to hearing from you.
